Research graph
References from Current Management and the New Paradigm for ALK+ NSCLC After CROWN. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1371/journal.pone.0100866
10.1371/journal.pone.0100866 · External reference
10.3390/cancers9090118
10.3390/cancers9090118 · External reference
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · 2007 · External reference
Defining molecular risk in ALK+ NSCLC
10.18632/oncotarget.26886 · 2019 · External reference
Unresolved reference
External reference
Targeting ALK: Precision Medicine Takes on Drug Resistance
10.1158/2159-8290.cd-16-1123 · 2017 · External reference
10.3390/ph14020080
10.3390/ph14020080 · External reference
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lun g cancer in the ALEX study
10.1016/j.annonc.2020.04.478 · 2020 · External reference
Unresolved reference
External reference
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
10.1158/1078-0432.ccr-17-2588 · 2018 · External reference
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
10.1016/j.jtho.2019.08.003 · 2019 · External reference
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Posit ive NSCLC: Final Results of Phase 3 ALTA-1L Trial
10.1016/j.jtho.2021.07.035 · 2021 · External reference
Longitudinal therapy monitoring of ALK-positive lung cancer by combine d copy number and targeted mutation profiling of cell-free DNA
10.1016/j.ebiom.2020.103103 · 2020 · External reference
Early identification of disease progression in ALK-rearranged lung can er using circulating tumor DNA analysis
10.1038/s41698-021-00239-3 · 2021 · External reference
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
10.1038/s41416-023-02284-0 · 2023 · External reference
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kin ase inhibitors
10.1002/cam4.4663 · 2022 · External reference
Lorlatinib versus crizotinib as first-line treatment for advanced ALK- positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
10.1016/j.annonc.2026.05.692 · 2026 · External reference
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa1704795 · 2017 · External reference
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
10.1093/annonc/mds242 · 2013 · External reference
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa1810171 · 2018 · External reference
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
10.1056/nejmoa2027187 · 2020 · External reference
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
10.1056/nejmoa1408440 · 2014 · External reference
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
10.1056/nejmoa1713137 · 2018 · External reference
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study
10.1016/s2213-2600(22)00437-4 · 2023 · External reference
MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC
10.1016/j.jtho.2024.09.134 · 2024 · External reference
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
10.1200/jco.24.00581 · 2024 · External reference
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study
10.1200/jco.2024.42.17_suppl.lba8503 · 2024 · External reference
Unresolved reference
External reference
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: The tale of the tail
10.21037/tlcr-23-245 · 2023 · External reference
PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
10.1016/j.annonc.2025.12.011 · 2026 · External reference
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: Matching-adjusted indirect comparison
10.57264/cer-2025-0117 · 2026 · External reference
Expanding the portfolio of anti-ALK weapons
2015 · External reference
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study
10.1016/s0140-6736(17)30123-x · 2017 · External reference
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
10.1016/j.lungcan.2019.11.025 · 2020 · External reference
Unresolved reference
External reference
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study
10.1016/j.annonc.2025.09.018 · 2026 · External reference
10.1186/s12885-024-11916-4
10.1186/s12885-024-11916-4 · External reference
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer
10.1002/cam4.6241 · 2023 · External reference
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
10.1016/j.esmoop.2022.100527 · 2022 · External reference
Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
2024 · External reference
629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naive advanced ALK+ non-small cell lung cancer
10.1016/j.annonc.2024.10.662 · 2024 · External reference
Quality of life and symptom burden in patients with metastatic breast cancer
2016 · External reference
Health-related quality of life among patients with metastatic prostate cancer
10.1016/s0090-4295(96)00485-2 · 1997 · External reference
Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study
10.1016/j.oraloncology.2020.105014 · 2020 · External reference
Prognosis and patterns of progression in smoldering multiple myeloma
10.1182/bloodadvances.2025018021 · 2025 · External reference
Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01- 2020-ML42316)
10.1200/jco.2025.43.16_suppl.8015 · 2025 · External reference
Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN)
10.1200/jco.2026.44.16_suppl.8002 · 2026 · External reference
Depth of response and progression-free survival in patients with advanced ALK-positive non–small-cell lung cancer treated with lorlatinib
10.1200/jco.2025.43.16_suppl.8589 · 2025 · External reference
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L
10.1200/jco.2022.40.16_suppl.9072 · 2022 · External reference
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
10.1016/j.jtho.2023.05.021 · 2023 · External reference
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
10.21037/actr-23-4 · 2023 · External reference
Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine
10.1101/cshperspect.a039537 · 2021 · External reference
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: A narrative review
10.21037/tlcr-24-942 · 2025 · External reference
Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach
2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
10.1038/s43018-022-00399-6 · 2022 · External reference
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
10.1158/2159-8290.cd-16-0596 · 2016 · External reference
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
10.1158/2159-8290.cd-17-1256 · 2018 · External reference
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
10.1016/j.ebiom.2019.01.019 · 2019 · External reference
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
10.1158/2159-8290.cd-24-0231 · 2024 · External reference
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
10.1200/jco.2017.76.2294 · 2018 · External reference
EML4-ALK V3, treatment resistance, and survival: Refining the diagnosis of ALK+ NSCLC
10.21037/jtd.2018.05.61 · 2018 · External reference
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-s mall cell lung cancer
10.1093/annonc/mdw693 · 2017 · External reference
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer
10.1002/ijc.31275 · 2018 · External reference
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
10.1073/pnas.1322892111 · 2014 · External reference
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilizatio n and accelerated migration through NEK9 and NEK7
10.1242/jcs.241505 · 2020 · External reference
Comparative Genomics within and across Bilaterians Illuminates the Evolutionary History of ALK and LTK Proto-Oncogene Origination and Divers ification
10.1093/gbe/evaa228 · 2021 · External reference
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC
10.1200/jco.2026.44.16_suppl.8503 · 2026 · External reference
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
10.1016/j.annonc.2021.02.012 · 2021 · External reference
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Var iant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced N on-Small Cell Lung Cancer in the Global Phase III ALEX Study
10.1016/j.jtho.2019.03.007 · 2019 · External reference
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma
10.1002/ijc.31893 · 2019 · External reference
Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells
10.1126/science.1160058 · 2008 · External reference
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
10.1158/1078-0432.ccr-20-2853 · 2021 · External reference
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
10.1016/j.annonc.2024.08.2297 · 2024 · External reference
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
10.1016/j.jtho.2024.09.184 · 2024 · External reference
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review
10.21037/tlcr-22-708 · 2023 · External reference
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
10.21037/tlcr-21-32 · 2021 · External reference
Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
2023 · External reference
10.1186/s12885-025-14145-5
10.1186/s12885-025-14145-5 · External reference
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer
10.1097/jto.0b013e31827a892c · 2013 · External reference
Abstract 5787: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins an d leads to regression of ALK TKI-refractory tumors
10.1158/1538-7445.am2026-5787 · 2026 · External reference
Prophylactic peptide vaccine targeting resistance mutations in advance d ALK-positive lung cancer: Primary analysis from the ARCHER trial
10.1200/jco.2026.44.16_suppl.8517 · 2026 · External reference
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors
10.1016/j.jtho.2019.10.014 · 2020 · External reference
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK+ solid tumours
10.1016/j.annonc.2024.08.1310 · 2024 · External reference
10.3389/fonc.2021.670483
10.3389/fonc.2021.670483 · External reference
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
10.6004/jnccn.2025.7071 · 2025 · External reference
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (A LK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study
10.1200/jco.2025.43.16_suppl.tps8666 · 2025 · External reference
Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
10.1158/1535-7163.targ-23-b154 · 2023 · External reference
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial
10.1016/s1470-2045(17)30680-0 · 2017 · External reference
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo-[4,3-h]-[2,5,11]-benzoxa-diaza-cyclo-tetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
10.1021/jm500261q · 2014 · External reference
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer
2026 · External reference
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
10.1016/j.jtho.2025.09.018 · 2025 · External reference
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
10.1158/2159-8290.cd-22-0968 · 2023 · External reference
10.3389/fonc.2023.1144056
10.3389/fonc.2023.1144056 · External reference
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
10.1200/jco-25-00788 · 2025 · External reference
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
10.1056/nejmoa2604461 · 2026 · External reference
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer
10.1097/jto.0b013e31826146ee · 2012 · External reference
Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse
10.1101/pdb.prot077842 · 2014 · External reference
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
10.1111/cas.12284 · 2013 · External reference
Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib
2024 · External reference
Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
10.1016/j.ejca.2005.04.034 · 2005 · External reference
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
10.1016/s0140-6736(04)17098-0 · 2004 · External reference
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma
10.1016/j.urolonc.2017.09.004 · 2018 · External reference
10.1186/s12885-018-4209-9
10.1186/s12885-018-4209-9 · External reference
Consensus Recommendations for Management and Counseling of Adverse Eve nts Associated With Lorlatinib: A Guide for Healthcare Practitioners
10.1007/s12325-020-01365-3 · 2020 · External reference
A pragmatic guide for management of adverse events associated with lorlatinib
10.1016/j.lungcan.2024.107535 · 2024 · External reference
Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report
10.1111/bcp.15924 · 2024 · External reference
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer
10.1002/cpt.2228 · 2021 · External reference
Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification
10.1016/j.lungcan.2024.107954 · 2024 · External reference
Sample size adaptation designs and efficiency comparison with group sequential designs
10.1002/sim.10066 · 2024 · External reference
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
10.2147/lctt.s446878 · 2024 · External reference
1980P Tumor mutational burden (TMB) and proliferation as negative prognostic factors for ALK+ lung cancer: First results from the randomized ABP phase II trial
10.1016/j.annonc.2025.08.2604 · 2025 · External reference
From fatal disease to functional cure: 25 years of tyrosine kinase inh ibition in chronic myeloid leukemia
10.1038/s41375-026-02984-5 · 2026 · External reference
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patie nts With ALK-Rearranged NSCLC
10.1016/j.jtho.2023.08.007 · 2024 · External reference
EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
10.1158/2159-8290.cd-24-1417 · 2026 · External reference
Tumour mutational burden: Clinical utility, challenges and emerging improvements
10.1038/s41571-024-00932-9 · 2024 · External reference
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
10.1007/s00262-021-02981-w · 2021 · External reference
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
10.1038/s43018-023-00591-2 · 2023 · External reference
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
10.1056/nejmoa2119662 · 2022 · External reference
10.3390/cells9092095
10.3390/cells9092095 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Sample sizes based on the log-rank statistic in complex clinical trials
10.2307/2531910 · 1988 · External reference
The asymptotic properties of nonparametric tests for comparing survival distributions
10.1093/biomet/68.1.316 · 1981 · External reference
Sample-size formula for the proportional-hazards regression model
10.2307/2531021 · 1983 · External reference
Sample size computation for two-sample noninferiority log-rank test
10.1080/10543400500265736 · 2005 · External reference
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kin ase inhibitors
10.1002/cam4.4663 · ExternalCitation · doi-reference
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer
10.1002/cam4.6241 · ExternalCitation · doi-reference
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer
10.1002/cpt.2228 · ExternalCitation · doi-reference
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer
10.1002/ijc.31275 · ExternalCitation · doi-reference
Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma
10.1002/ijc.31893 · ExternalCitation · doi-reference
Sample size adaptation designs and efficiency comparison with group sequential designs
10.1002/sim.10066 · ExternalCitation · doi-reference
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
10.1007/s00262-021-02981-w · ExternalCitation · doi-reference
Consensus Recommendations for Management and Counseling of Adverse Eve nts Associated With Lorlatinib: A Guide for Healthcare Practitioners
10.1007/s12325-020-01365-3 · ExternalCitation · doi-reference
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lun g cancer in the ALEX study
10.1016/j.annonc.2020.04.478 · ExternalCitation · doi-reference
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs
10.1016/j.annonc.2021.02.012 · ExternalCitation · doi-reference
1253O Phase I/II ALKOVE-1 study of NVL-655 in ALK+ solid tumours
10.1016/j.annonc.2024.08.1310 · ExternalCitation · doi-reference
LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
10.1016/j.annonc.2024.08.2297 · ExternalCitation · doi-reference
629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-naive advanced ALK+ non-small cell lung cancer
10.1016/j.annonc.2024.10.662 · ExternalCitation · doi-reference
1980P Tumor mutational burden (TMB) and proliferation as negative prognostic factors for ALK+ lung cancer: First results from the randomized ABP phase II trial
10.1016/j.annonc.2025.08.2604 · ExternalCitation · doi-reference
Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the phase III ALEX study
10.1016/j.annonc.2025.09.018 · ExternalCitation · doi-reference
PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
10.1016/j.annonc.2025.12.011 · ExternalCitation · doi-reference
Lorlatinib versus crizotinib as first-line treatment for advanced ALK- positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
10.1016/j.annonc.2026.05.692 · ExternalCitation · doi-reference
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
10.1016/j.ebiom.2019.01.019 · ExternalCitation · doi-reference
Longitudinal therapy monitoring of ALK-positive lung cancer by combine d copy number and targeted mutation profiling of cell-free DNA
10.1016/j.ebiom.2020.103103 · ExternalCitation · doi-reference
Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
10.1016/j.ejca.2005.04.034 · ExternalCitation · doi-reference
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer
10.1016/j.esmoop.2022.100527 · ExternalCitation · doi-reference
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Var iant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced N on-Small Cell Lung Cancer in the Global Phase III ALEX Study
10.1016/j.jtho.2019.03.007 · ExternalCitation · doi-reference
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
10.1016/j.jtho.2019.08.003 · ExternalCitation · doi-reference
Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors
10.1016/j.jtho.2019.10.014 · ExternalCitation · doi-reference
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Posit ive NSCLC: Final Results of Phase 3 ALTA-1L Trial
10.1016/j.jtho.2021.07.035 · ExternalCitation · doi-reference
Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC
10.1016/j.jtho.2023.05.021 · ExternalCitation · doi-reference
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patie nts With ALK-Rearranged NSCLC
10.1016/j.jtho.2023.08.007 · ExternalCitation · doi-reference
MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC
10.1016/j.jtho.2024.09.134 · ExternalCitation · doi-reference
MA12.03 FLAURA2: Resistance, and Impact of Baseline TP53 Alterations in Patients Treated With 1L Osimertinib ± Platinum-Pemetrexed
10.1016/j.jtho.2024.09.184 · ExternalCitation · doi-reference
PL02.15 Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pre-treated Patients with Advanced/Metastatic ROS1+ NSCLC
10.1016/j.jtho.2025.09.018 · ExternalCitation · doi-reference
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
10.1016/j.lungcan.2019.11.025 · ExternalCitation · doi-reference
A pragmatic guide for management of adverse events associated with lorlatinib
10.1016/j.lungcan.2024.107535 · ExternalCitation · doi-reference
Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification
10.1016/j.lungcan.2024.107954 · ExternalCitation · doi-reference
Annual malignant transformation rate of oral leukoplakia remains consistent: A long-term follow-up study
10.1016/j.oraloncology.2020.105014 · ExternalCitation · doi-reference
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma
10.1016/j.urolonc.2017.09.004 · ExternalCitation · doi-reference
Health-related quality of life among patients with metastatic prostate cancer
10.1016/s0090-4295(96)00485-2 · ExternalCitation · doi-reference
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial
10.1016/s0140-6736(04)17098-0 · ExternalCitation · doi-reference
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, open-label, phase 3 study
10.1016/s0140-6736(17)30123-x · ExternalCitation · doi-reference
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial
10.1016/s1470-2045(17)30680-0 · ExternalCitation · doi-reference
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study
10.1016/s2213-2600(22)00437-4 · ExternalCitation · doi-reference
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo-[4,3-h]-[2,5,11]-benzoxa-diaza-cyclo-tetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
10.1021/jm500261q · ExternalCitation · doi-reference
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · ExternalCitation · doi-reference
From fatal disease to functional cure: 25 years of tyrosine kinase inh ibition in chronic myeloid leukemia
10.1038/s41375-026-02984-5 · ExternalCitation · doi-reference
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
10.1038/s41416-023-02284-0 · ExternalCitation · doi-reference
Tumour mutational burden: Clinical utility, challenges and emerging improvements
10.1038/s41571-024-00932-9 · ExternalCitation · doi-reference
Early identification of disease progression in ALK-rearranged lung can er using circulating tumor DNA analysis
10.1038/s41698-021-00239-3 · ExternalCitation · doi-reference
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
10.1038/s43018-022-00399-6 · ExternalCitation · doi-reference
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
10.1038/s43018-023-00591-2 · ExternalCitation · doi-reference
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
10.1056/nejmoa1408440 · ExternalCitation · doi-reference
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa1704795 · ExternalCitation · doi-reference
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
10.1056/nejmoa1713137 · ExternalCitation · doi-reference
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
10.1056/nejmoa1810171 · ExternalCitation · doi-reference
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
10.1056/nejmoa2027187 · ExternalCitation · doi-reference
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
10.1056/nejmoa2119662 · ExternalCitation · doi-reference
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
10.1056/nejmoa2604461 · ExternalCitation · doi-reference
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
10.1073/pnas.1322892111 · ExternalCitation · doi-reference
Sample size computation for two-sample noninferiority log-rank test
10.1080/10543400500265736 · ExternalCitation · doi-reference
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
10.1093/annonc/mds242 · ExternalCitation · doi-reference
Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-s mall cell lung cancer
10.1093/annonc/mdw693 · ExternalCitation · doi-reference
The asymptotic properties of nonparametric tests for comparing survival distributions
10.1093/biomet/68.1.316 · ExternalCitation · doi-reference
Comparative Genomics within and across Bilaterians Illuminates the Evolutionary History of ALK and LTK Proto-Oncogene Origination and Divers ification
10.1093/gbe/evaa228 · ExternalCitation · doi-reference
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer
10.1097/jto.0b013e31826146ee · ExternalCitation · doi-reference
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer
10.1097/jto.0b013e31827a892c · ExternalCitation · doi-reference
Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine
10.1101/cshperspect.a039537 · ExternalCitation · doi-reference
Generation of drug-resistant tumors using intermittent dosing of tyrosine kinase inhibitors in mouse
10.1101/pdb.prot077842 · ExternalCitation · doi-reference
Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report
10.1111/bcp.15924 · ExternalCitation · doi-reference
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
10.1111/cas.12284 · ExternalCitation · doi-reference
Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells
10.1126/science.1160058 · ExternalCitation · doi-reference
Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
10.1158/1078-0432.ccr-17-2588 · ExternalCitation · doi-reference
Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
10.1158/1078-0432.ccr-20-2853 · ExternalCitation · doi-reference
Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
10.1158/1535-7163.targ-23-b154 · ExternalCitation · doi-reference
Abstract 5787: TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins an d leads to regression of ALK TKI-refractory tumors
10.1158/1538-7445.am2026-5787 · ExternalCitation · doi-reference
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
10.1158/2159-8290.cd-16-0596 · ExternalCitation · doi-reference
Targeting ALK: Precision Medicine Takes on Drug Resistance
10.1158/2159-8290.cd-16-1123 · ExternalCitation · doi-reference
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
10.1158/2159-8290.cd-17-1256 · ExternalCitation · doi-reference
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
10.1158/2159-8290.cd-22-0968 · ExternalCitation · doi-reference
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
10.1158/2159-8290.cd-24-0231 · ExternalCitation · doi-reference
EML4−ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis
10.1158/2159-8290.cd-24-1417 · ExternalCitation · doi-reference
Prognosis and patterns of progression in smoldering multiple myeloma
10.1182/bloodadvances.2025018021 · ExternalCitation · doi-reference
10.1186/s12885-018-4209-9
10.1186/s12885-018-4209-9 · ExternalCitation · doi-reference
10.1186/s12885-024-11916-4
10.1186/s12885-024-11916-4 · ExternalCitation · doi-reference
10.1186/s12885-025-14145-5
10.1186/s12885-025-14145-5 · ExternalCitation · doi-reference
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
10.1200/jco-25-00788 · ExternalCitation · doi-reference
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
10.1200/jco.2017.76.2294 · ExternalCitation · doi-reference
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L
10.1200/jco.2022.40.16_suppl.9072 · ExternalCitation · doi-reference
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study
10.1200/jco.2024.42.17_suppl.lba8503 · ExternalCitation · doi-reference
Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: Final analysis of ALNEO phase II trial (GOIRC-01- 2020-ML42316)
10.1200/jco.2025.43.16_suppl.8015 · ExternalCitation · doi-reference
Depth of response and progression-free survival in patients with advanced ALK-positive non–small-cell lung cancer treated with lorlatinib
10.1200/jco.2025.43.16_suppl.8589 · ExternalCitation · doi-reference
Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (A LK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study
10.1200/jco.2025.43.16_suppl.tps8666 · ExternalCitation · doi-reference
Neoadjuvant lorlatinib in stage III NSCLC harboring ALK fusion: A phase 2 multicenter study (LORIN)
10.1200/jco.2026.44.16_suppl.8002 · ExternalCitation · doi-reference
ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC
10.1200/jco.2026.44.16_suppl.8503 · ExternalCitation · doi-reference
Prophylactic peptide vaccine targeting resistance mutations in advance d ALK-positive lung cancer: Primary analysis from the ARCHER trial
10.1200/jco.2026.44.16_suppl.8517 · ExternalCitation · doi-reference
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
10.1200/jco.24.00581 · ExternalCitation · doi-reference
EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilizatio n and accelerated migration through NEK9 and NEK7
10.1242/jcs.241505 · ExternalCitation · doi-reference
10.1371/journal.pone.0100866
10.1371/journal.pone.0100866 · ExternalCitation · doi-reference
Defining molecular risk in ALK+ NSCLC
10.18632/oncotarget.26886 · ExternalCitation · doi-reference
An ever-stronger case for circulating tumor DNA monitoring in ALK+ lung cancer
10.21037/actr-23-4 · ExternalCitation · doi-reference
EML4-ALK V3, treatment resistance, and survival: Refining the diagnosis of ALK+ NSCLC
10.21037/jtd.2018.05.61 · ExternalCitation · doi-reference
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies
10.21037/tlcr-21-32 · ExternalCitation · doi-reference
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review
10.21037/tlcr-22-708 · ExternalCitation · doi-reference
Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: The tale of the tail
10.21037/tlcr-23-245 · ExternalCitation · doi-reference
Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: A narrative review
10.21037/tlcr-24-942 · ExternalCitation · doi-reference
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
10.2147/lctt.s446878 · ExternalCitation · doi-reference
Sample-size formula for the proportional-hazards regression model
10.2307/2531021 · ExternalCitation · doi-reference
Sample sizes based on the log-rank statistic in complex clinical trials
10.2307/2531910 · ExternalCitation · doi-reference
10.3389/fonc.2021.670483
10.3389/fonc.2021.670483 · ExternalCitation · doi-reference
10.3389/fonc.2023.1144056
10.3389/fonc.2023.1144056 · ExternalCitation · doi-reference
10.3390/cancers9090118
10.3390/cancers9090118 · ExternalCitation · doi-reference
10.3390/cells9092095
10.3390/cells9092095 · ExternalCitation · doi-reference
10.3390/ph14020080
10.3390/ph14020080 · ExternalCitation · doi-reference
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: Matching-adjusted indirect comparison
10.57264/cer-2025-0117 · ExternalCitation · doi-reference
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study
10.6004/jnccn.2025.7071 · ExternalCitation · doi-reference
